Table 3.
Finerenone Induces Early Amelioration of Cardiac Function in CKD (Protocol 3)
| CKD (n=6) | CKD+finerenone 7 days (n=8) | |
|---|---|---|
| SBP, mm Hg | 145±12.5 | 131±9 |
| LVESP, mm Hg | 142±12 | 126±9 |
| dP/dtmax, mm Hg/s | 9133±814 | 9051±1042 |
| LVESPVR, RVU/mm Hg | 23.2±1.6 | 26.9±0.8* |
| LVEDP, mm Hg | 7.5±0.6 | 6.4±0.4 |
| dP/dtmin, mm Hg/s | 12 364±1360 | 11 848±1440 |
| τ, ms | 11±0.5 | 8.5±0.3* |
| LVEDPVR, RVU/mm Hg | 3.9±0.2 | 2.9±0.3* |
| HR, bpm | 346±15 | 374±5 |
| Septum tissue perfusion, (mL/min) | 5.3±0.7 | 7.2±0.7 |
Data are presented as the mean±SEM, n=6–8. Student's t test was used for statistical analysis. CKD indicates chronic kidney disease; HR, heart rate; LVEDP, left ventricular end‐diastolic pressure; LVEDPVR, left ventricular end‐diastolic pressure volume relationship; LVESP, left ventricular end‐systolic pressure; LVESPVR, left ventricular end‐systolic pressure volume relationship; SBP, systolic blood pressure; and τ, time constant of relaxation.
*
P<0.05 vs CKD.